Britain and America have forged a landmark bilateral deal that will preserve no levies on British pharmaceutical shipments being sold in the American market.
Agreement Details of the Deal
Under the terms of the agreement, the UK has pledged to increase expenditure on pharmaceuticals through the public health system. This pledge guarantees that import taxes on these crucial products will remain at nothing for a duration of three years.
This deal is in response to earlier threats to significantly raise import taxes on branded drug products, with figures discussed up to one hundred percent.
"This deal between the United Kingdom reinforces the international landscape for innovative medicines and establishes long-overdue fairness to American-British medicine commerce," a statement declared.
Trade Importance
Pharmaceuticals are one of the Britain's most significant export categories to the United States, which is easily the largest destination for major companies like GSK and AstraZeneca.
Export figures show that in the 12 months prior to September, the UK sold medicines totaling £11.1bn to the US. This amount made up 17.4% of all goods exports in that timeframe.
"This agreement safeguards jobs, stimulates capital expenditure and sets the stage for the UK to establish itself as a worldwide center for medical research," a government official commented.
Detailed UK Commitments
The deal involves several key commitments from the British government:
- Higher Cost Ceiling: The UK will increase the affordability limit at which it deems new treatments to be prohibitively costly by a quarter.
- Increased NHS Spending: There is a aim to double total NHS spending on treatments from 0.3% of GDP to 0.6 percent over the following ten-year period.
- Rebate Cap: The percentage manufacturers must pay back to the NHS to control costs will be restricted at 15%. Last year, repayments topped 20%.
Industry Background
The deal takes place against a ongoing tension between the sector and the UK government over drug pricing and regulatory access.
This friction were heightened by arguments that American customers were paying significantly more for the equivalent treatments than patients in the Britain and the EU.
Over the last 18 months, several large pharmaceutical investments in the UK have been delayed or scrapped, while major investments have been directed toward projects in the United States.
The Science Minister acknowledged that the NHS had to invest a greater share on treatments, noting that its spending on drugs had decreased as a share of its resources over the last ten years.
